Remedy Plan Therapeutics
PrivateLast Round
VC Round
May 13, 2025
Total Funding Raised
$22.91M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Remedy Plan Therapeutics operates in Healthcare & Life Sciences and is based in Gaithersburg, Maryland. Its latest recorded funding round was a VC Round in May 2025.
Remedy Plan Therapeutics is a biotechnology company developing a pipeline of novel, hyperbolic NAMPT inhibitors to treat a range of diseases including solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remedy Plan Therapeutics Comparables
Compare Remedy Plan Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoTartis, Inc. | 90% | |
| Dracen Pharmaceuticals, Inc. | 77% | |
| Valerio Therapeutics | 74% |
For institutional investors. Book with your work email.
Remedy Plan Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 13, 2025 | ||||
| Series A | Aug 1, 2023 | ||||
| Early Funding | Nov 20, 2018 | ||||
| Grant | Sep 20, 2018 | ||||
| Crowdfunding | Nov 6, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Remedy Plan Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alexandria Venture Investments | VC Round |
| Schooner Capital | VC Round, Early Funding |
| Maryland Tech Council | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
Grew 22% QoQ, from 18 to 22 employees.
- Sep 12, 2026
Monthly visitors grew 55% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 15, 2026
On Sep 15th '26, Remedy Plan closes approximately $30 million in Series A extension financing, classified as Series A1, with participation from Schooner Capital and primarily existing investors to advance RPT1G, expand its Phase 1 study, initiate solid-tumor clinical activities, and develop additional NAMPT inhibitors.
- hiresSep 15, 2026
Remedy Plan appoints Oleg Zernovak, M.D. as Vice President, Clinical Development on Sep 15th '26, bringing more than 20 years of drug development experience in hematologic malignancies and clinical trial execution.
For institutional investors. Book with your work email.
Remedy Plan Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Remedy Plan Therapeutics's valuation, stock price, and market status.
Is Remedy Plan Therapeutics a public or private company?
Remedy Plan Therapeutics is a private company.
What is the current stock price of Remedy Plan Therapeutics?
Remedy Plan Therapeutics is a private company, so its shares have no public market price. Caplight tracks Remedy Plan Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Remedy Plan Therapeutics worth (valuation)?
Valuation information for Remedy Plan Therapeutics is not publicly available.
Can I buy Remedy Plan Therapeutics stock?
Remedy Plan Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Remedy Plan Therapeutics's last funding round?
Remedy Plan Therapeutics's most recent funding round was VC Round on May 13, 2025.
Who are the main investors in Remedy Plan Therapeutics?
Key investors in Remedy Plan Therapeutics include Alexandria Venture Investments, Schooner Capital, Maryland Tech Council.
Will Remedy Plan Therapeutics IPO soon?
No public IPO plans have been announced for Remedy Plan Therapeutics.
How can I track Remedy Plan Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Remedy Plan Therapeutics's shares on secondary markets.